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ImmunosenescenceAlzheimer's disease (AD) is characterized by extracellular senile plaques in the brain, containing amyloid-β peptide
(Aβ).We identify immunological differencesbetweenADpatients andage-matched controls greater than those related
to age itself. The biggest differences were in the CD4+ rather than the CD8+ T cell compartment resulting in lower
proportions of naïve cells,more late-differentiated cells andhigher percentages of activatedCD4+CD25+Tcellswith-
out a Treg phenotype inADpatients. Changes to CD4+cellsmight be the result of chronic stimulation byAβpresent in
the blood. These ﬁndings have implications for diagnosis and understanding the aetiology of the disease.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is an age-related neurological disorder
that leads to progressive dementia. AD is histopathologically charac-
terized by extracellular amyloid plaques, formed by amyloid beta
peptide (Aβ), and by intracellular neuroﬁbrillary tangles. Deposits of
highly aggregated amyloid beta ﬁbrils trigger an inﬂammatory pro-
cess that plays an important role in AD pathogenesis (Grifﬁn and
Mrak, 2002; Akiyama et al., 2000; Rojo et al., 2008). It was suggested
that the inﬂammation occurring in the brain of AD patients has sys-
temic parallels, and there are many reports supporting the concept
that AD is a systemic inﬂammatory disease (Britschgi and Wyss-
Coray, 2007). A number of reports also show that more T-cells are ac-
tivated in AD patients than age-matched controls, and that these cells
are present both in the periphery and as inﬁltrates in the brain (Togo
et al., 2002; Town et al., 2005; Li et al., 2009). In vitro studies have
shown that Aβ induces the production of chemokines such as MIP-
1α, RANTES and MCP-1 by PBMCs of AD patients and the expression
of CCR5 on brain endothelial cells; this might enhance the migration
of peripheral T cells across the blood brain barrier (BBB) (Li et al.,
2009; Reale et al., 2008). We have recently demonstrated that PBMC
from AD patients produce high levels of RANTES and MIP-1β after
in vitro activation with Aβ 42, and that the expression of CCR2 and
CCR5 on T cells and of CCR5 on B cells is increased in AD patients after
in vitro stimulation of PBMC with Aβ peptide (Pellicanò et al., 2010).x: +49 7071 29 4677.
n.de (M. Pellicanò).
l rights reserved.Furthermore, evidence is accumulating for an altered distribution of
lymphocyte subsets in the peripheral blood of AD patients compared to
age-matched controls (Speciale et al., 2007). A general decrease of B
and T cell numbers has been reported, while the number of natural killer
(NK) cells was not affected (Speciale et al., 2007; Richartz-Salzburger
et al., 2007).Within the T cell population, a slight increase of the percent-
age of CD4+ and a decrease of CD8+ lymphocytes was found (Richartz-
Salzburger et al., 2007). We recently reported a signiﬁcant reduction of
the percentage of naïve CD4+ cells (CD45RA+CCR7+), and an increase
of effector memory (CD45RA-CCR7-) and TEMRA (CD45RA+CCR7-)
cells in a pilot study of CanadianADpatients (Larbi et al., 2009) compared
to age-matched controls. A reduction of CD4+CD25high cells, considered
as potentially Treg cells, was also found (Larbi et al., 2009). No differences
were discernible between AD patients and controls within the CD8 com-
partment because the effects of age were already somarked in the latter.
Our previous study was limited to a small group of Canadian pa-
tients with mild AD. To determine whether the immune signatures
seen in these patients are to be expected generally in AD, we under-
took a more detailed analysis on a completely different population
from Italy. We have studied CD4+ and CD8+ subsets investigating
the expression of the isoforms of CD45 (CD45RA and CD45RO),
which can be informative for the differentiation stage of T cells
(Michie et al., 1992; Sallusto et al., 1999), and the expression of two
major positive T cell costimulatory receptors CD27 and CD28 and
two negative receptors expressed by late-stage differentiated cells,
CD57 and KLRG1 (sometimes referred to as markers of “senescence”).
CD57 is expressed on NK cells and late-stage CD8+ T cells with slight
expression on CD4+ cells sometimes reported (Tarazona et al., 2000;
Fig. 1. Frequency of CD4+and CD8+ lymphocytes in peripheral blood. Percentages of CD4+(A)
and CD8+ T lymphocytes (B) within CD3+ cells, and the CD4:CD8 ratio (C) in 11 young con-
trols (squares), 21 healthy old (circles) and 40ADpatients (diamonds). Bars representmedians.
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expressed on larger proportions of CD4+ T cells as well as CD8+
T cells and NK cells. It was initially suggested that the expression
of KLRG-1 marked replicatively-senescent cells (Voehringer et al.,
2001; Voehringer et al., 2002). Finally we have analyzed the percentage
of the activated CD4+CD25+ population that is increased in AD pa-
tients compared to young and old subjects. The emerging data
suggest the existence of characteristic immune proﬁle limited to the
CD4+T cell subset in AD, which might be useful diagnostically as well
as in furthering understanding of the etiology of this intractable disease.
2. Material and methods
2.1. Subjects
A total of 40 AD patients (22 women and 18 men; age range:
62–94 years, mean 75±8), 21 healthy old controls (11 women and
10 men; age range: 72–92 years, mean 84±5) and 11 young subjects
(4 women and 7 men; age range: 21–28 years, mean 25±2) from
Italy have been investigated. None of the controls had a history of
neurodegenerative disorders. Diagnosis of probable ADwas according
to standard clinical procedures and followed the NINCDS/ADRDA and
DSM-III-R criteria (McKhann et al., 1984; American Psychiatric
Association, 1987). Cognitive performance and alterations were mea-
sured according to the mini-mental state evaluation (MMSE) and the
global deterioration scale. The MMSE was normal (30/30) for the
young and the healthy elderly groups. The patients were mild-to-
moderate AD with MMSE scores between 25 and 10, of which 16
had mild AD (MMSE mean 22.8±2) and 24 moderate AD (MMSE
mean 14.4±2.9). All AD cases were deﬁned as sporadic because
their family history did not mention any ﬁrst-degree relative with de-
mentia. AD patients included in the study did not present with any
major co-morbidity such as cancer, symptomatic (present or previ-
ous) cardiovascular diseases, or major inﬂammatory diseases such
as autoimmunity and infections. Control subjects also had complete
neurological examinations and were judged to be in good health
based on their clinical history and blood tests (complete blood cell
count, erythrocyte sedimentation rate, glucose, urea nitrogen, creati-
nine, electrolytes, C-reactive protein, liver function tests, iron, proteins,
cholesterol, triglycerides). The controls were collected from the same
population as the patient cohort. The University Hospital Ethics Com-
mittee approved the study, and informed consent was obtained from
all guardians of patients and controls according to Italian law.
All subjects were tested for CMV serostatus by ELISA using CMV-
IgG-ELISA PKS assays (Genesis Diagnostics, UK). All the elderly sub-
jects were positive for CMV antibody (both healthy old and AD)
while none of the young were infected.
Whole blood was collected by venepuncture in vacutainer tubes
containing ethylenediaminetetraacetic acid. Peripheral blood mono-
nuclear cells (PBMC) were separated using a Ficoll/Hypaque gradient
and frozen according to standard protocols.
2.2. Flow cytometry
To analyze T lymphocyte subsets, direct immunoﬂuorescence
was performed with anti-CD3-AlexaFluor700, CD8-PercP, CD28-
PercP-Cy5.5 (Becton Dickinson, Heidelberg, Germany), CD4-Qdot705,
CD27-Qdot605 (Invitrogen, Karlsruhe, Germany), CD45RO-eFluor650
(eBioscience, San Diego, California), CD45RA-PaciﬁcBlue (Bio-Legend,
Biozol, Eching, Germany), and CD57-FITC (Immunotools, Friesoythe,
Germany). For indirect immunoﬂuorescence, anti-human KLRG1
(clone 13A2), kindly provided by Prof. H.P. Pircher (University of
Freiburg, Germany), was used as primary antibody. The secondary an-
tibody was goat anti-mouse IgG-Qdot565 (Invitrogen). Treg analysis
was performed by extracellular labeling with anti-CD3-AlexaFluor700
(Becton Dickinson), anti-CD4-Qdot705 (Invitrogen), anti-CD127-Alexa647 (Bio-Legend) and intracellular staining with anti-FoxP3
with (Bio-Legend).
Cell viability was determined with RedVid (Invitrogen). All staining
steps were performed in PFEA buffer (PBS, 2% FCS, 2 mM EDTA and 0.01%
Na Azide). Blocking of non-speciﬁc binding sites was accomplished using
human immunoglobulin GAMUNEX (Bayer, Leverkusen, Germany) or
mouse serum (Caltag/Invitrogen, Karlsruhe, Germany). For each experi-
ment, cells or mouse/rat κ-chain Comp Beads (Becton Dickinson) were
stainedwith the corresponding ﬂuorochrome-labeled antibodies and incu-
bated for 20min at 4 °C in the dark. Human unstained cells were used as
negative controls. After washing with PFEA, the cells or beads were re-
suspended and measured using an LSR-II ﬂow cytometer and the acquisi-
tion software FACSDiva (Becton Dickinson). Data were analyzed using
FlowJo software (Tree Star, Portland, OR). For data analysis, dead cells (Red-
Vid-positive), were excluded. CD3+ living cells were gatedwithin the SSC/
FSC lymphocyte gate. Further analysis was performed using CD3+CD4+
and CD3+CD8+ gated populations.
2.3. Statistics
All statistical analyses were performed with Graph-Pad Prism 4.0
using the Mann–Whitney nonparametric U test to compare two
independent groups. The Bonferroni correction for multiple compari-
sons was applied. Differences were considered signiﬁcant with a
p value≤0.005. Signiﬁcant differences are indicated by * p≤0.005,
** p≤0.001, *** p≤0.0005 as mentioned in the ﬁgure legends.
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3.1. Frequency of CD4 and CD8 cells in young controls, old controls and
AD patients
It has been shown that the CD4:CD8 ratio can be a marker predic-
tive of mortality in an elderly Swedish population. A cluster of this
marker and others constitutes the Immune Risk Proﬁle (IRP) predict-
ing mortality in the very elderly on 2, 4 and 6-year follow-up
(Pawelec et al., 2002). Because our aim was to investigate the im-
mune status in AD patients, who have a reduced lifespan compared
to healthy old individuals, we have analyzed CD4 and CD8 distribu-
tion in PBMC of AD patients compared to healthy age-matched old
controls and young subjects. As shown in Fig. 1A, there is a slight
but non-signiﬁcant decrease in the median percentage of CD4+
cells within the CD3+ T cell population in AD patients as a group
compared to the age-matched controls. The decrease in CD4+ cells
was marginally more marked for AD patients compared to young con-
trols, but this difference also failed to reach signiﬁcance. However,
within the broad range of values recorded in this group, individual
AD patients showed the lowest percentages of CD4 cells, lower even
than the lowest age-matched controls. These tendencies were not ob-
served in the CD8 compartment (Fig. 1B). These slight shifts also
failed to affect the CD4:CD8 ratio in the three groups. However, indi-
vidual patients within the AD group again showed the most extreme
differences, with the lowest CD4:8 ratios (Fig. 1C). The CD4:8 ratio
cut-off for inclusion in the IRP is b1; the data summarized in Fig. 1C
indicate that, as expected, no young controls fall into this group,
whereas 1/21 old controls (5%), but 5/40 AD patients (12.5%) have a
CD4:8 ratio of b1. No signiﬁcant differences were observed compar-
ing CD4:8 ratios obtained from subjects with mild vs moderate AD
(data not shown).3.2. Costimulatory molecules on CD4+ and CD8+ cells
The distribution of T cells at different stages of differentiation
(naïve, memory etc.) is likely to be more important than the mereFig. 2. CD28 and CD27 expression in young controls, old controls and AD patients. PBMC of 11 youn
for CD3, CD4, CD8, CD27, CD28 to distinguish early- and late-differentiated cells. The percentag
and CD8+ T cells (B). Bars represent medians. Signiﬁcant differences are indicated by *** p≤0percentages of CD4 and CD8 cells. We therefore compared T cell dif-
ferentiation status in AD patients versus old controls, using multiple
markers including the CD27 and CD28 costimulatory molecules,
which are crucial for T cell activation. It has been reported that ex-
pression of these two markers is reduced proportional to the degree
of differentiation of the T cell (Romero et al., 2007). Naïve cells are
CD28+CD27+ while the latest stage of T cell differentiation is ac-
companied by the loss of both CD28 and CD27 (Koch et al., 2008).
As shown in Fig. 2A (left-hand side) there is a slight but not signiﬁ-
cant decrease in the percentage of CD28+CD27+ cells within the
CD4+ subset in AD patients compared to the elderly controls. The
young controls in this population have a highly signiﬁcantly greater
percentage of CD27+CD28+ cells within the CD4 subset than either
the old controls or AD patients, albeit more marked in the latter. Re-
ciprocally, signiﬁcantly increased percentages of late-differentiated
CD4+ cells (CD28-CD27-) are seen in both elderly controls and AD
patients, with no real difference between the latter two groups
(Fig. 2A, right-hand side).
Within the CD8 subset, the anticipated highly signiﬁcantly lower
percentage of CD27+CD28+ and higher percentage of double-
negative cells is seen in the old compared to the young, with no differ-
ence at all between AD patients and age-matched controls (Fig. 2B).3.3. Frequencies of naïve and late-differentiated cells within the
CD4+ and the CD8+ populations
Although assessing the expression of CD27 and CD28 provides
some information on T cell differentiation status and potentially T
cell function, a combination of markers is required to distinguish be-
tween naïve and memory cells. To this end, we have analyzed the ex-
pression of CD45RA and CD45RO together with CD27 and CD28.
CD45RA and CD45RO are isoforms of the protein phosphatase CD45,
with naïve cells more likely to express CD45RA and memory cells
CD45RO. However, re-expression of CD45RA by late-differentiated
memory cells makes this marker unsuitable for identifying naïve
cells by itself (Hamann et al., 1997). Thus we used four markers to
identify naïve and memory subsets, as follows: CD28+CD27+g controls (squares), 21 healthy old (circles) and 40 ADpatients (diamonds)were stained
e of CD28+CD27+ (early) and CD28-CD27- (late) lymphocytes are shown for CD4+ (A),
.0005 by Mann–Whitney nonparametric U testing with Bonferroni correction.
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CD45RO+late differentiated, comparing CD4 and CD8 lymphocytes
in the young, old and AD patients. Fig. 3A gives examples of ﬂow cyto-
metry data as dot-plots for CD4+ cells from a young donor, an old
control and an AD patient, and Fig 3B shows the summed data from
11 young controls, 21 healthy elderly and the 40 AD patients. Al-
though the percentages of naïve CD4 cells in both old controls and
AD patients are very low relative to the young, the decrease in AD
compared to age-matched controls reaches signiﬁcance. Similarly,
the reciprocal increase in late-differentiated memory cells is also sig-
niﬁcantly greater in AD patients than in age-matched controls. These
differences are not seen in the CD8 subset analyzed in the same man-
ner (Fig. 4).
The same analysis was done comparing patients with mild vs. mod-
erate AD and no signiﬁcant differences have been observed (data not
shown).3.4. Expression of “senescence” markers on CD4+ and CD8+ T cells
In an effort to reﬁne our deﬁnition of naïve and late-differentiated T
cells in AD, in order to increase our ability to distinguish immune signa-
tures in AD from age-associated changes in age-matched controls, we
employed two additional markers. Previous studies have shown thatFig. 3. CD4+ naïve and late-differentiated subsets in AD patients and controls. PBMCs wer
differentiated cells. (3A) Representative dot plots of naïve (top) and late-differentiated (bott
panels) and in an AD patient (right panels). (3B) Percentages of CD28+CD27+CD45RA+
(right) of 11 young controls (black squares), 21 healthy old (black circles) and 40 AD patien
AD have been assessed by Mann–Whitney nonparametric U testing with Bonferroni correcchronic antigenic stimulation of the immune system, such as in the
case of cytomegalovirus (CMV) infection, led to increased frequencies
of late- or even end-stage differentiated CD8+T cells. These cells highly
express KLRG1 and CD57 which are sometimes designed “senescence”
markers (Ibegbu et al., 2005). Therefore, we tested the possibility that
putative chronic stimulation of the immune system by AD-derived
end products (Aβ) would inﬂuence the expression of these two
markers. As shown in Fig. 5, within the CD4 subset, the percentage of
cells expressing KLRG-1 was very signiﬁcantly greater in AD patients
compared to age-matched controls (Fig. 5, upper right-hand panel).
This was not the case for their CD8+ cells (Fig. 5, lower right-hand
panel), and nor was it the case for either CD4 or CD8 cells regarding
their expression of CD57 (Fig. 5, left-hand panels). Also in this case no
signiﬁcant differences have been observed comparing data obtained
from patients with mild vs. moderate AD (data not shown).3.5. CD4+CD25+ cells and Tregs
CD25, the IL-2 receptor α chain, is expressed by activated T cells,
but is also taken as a marker of regulatory T cells. We have conﬁrmed
a signiﬁcantly higher frequency of CD4+CD25+ T cells in AD pa-
tients compared to both groups of controls. Examples of staining for
CD4 and CD25 in a young control (left-hand panel), old controle stained with CD3, CD4, CD28, CD27, CD45RA, CD45RO to identify naïve and late-
om) CD4+ T cell distribution in a young control (left panels), in an old control (middle
CD45RO- naïve cells (left) and of CD28-CD27-CD45RA+CD45RO+differentiated cells
ts (black diamonds). Bars represent medians. Differences between control subjects and
tion. Signiﬁcant differences are indicated by * p≤0.005, *** p≤0.0005.
Fig. 4. CD8+ naïve and late-differentiated subsets in AD patients and controls. The per-
centages of CD8+ naïve CD28+CD27+CD45RA+CD45RO- cells (4A) and late-
differentiated CD28-CD27-CD45RA+CD45RO+cells (4B) within PBMC of 11 young
controls (black squares), 21 healthy old (black circles) and 40 AD patients (black dia-
monds) are shown. The bar represents the median. Differences between control sub-
jects and AD have been evaluated by Mann–Whitney nonparametric U testing with
Bonferroni correction. Signiﬁcant differences are indicated by *** p≤0.0005.
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the summed data from 11 young controls, 21 healthy old and 40 AD
patients in Fig. 6B, left panel. There is a highly signiﬁcant difference
between the old controls and the AD patients, with the latter posses-
sing a greater percentage of CD4+ CD25+ cells. However, CD25 by
itself is not sufﬁcient to identify regulatory T cells; to this end we
used FoxP3 nuclear staining and weak CD127 surface staining as
markers for these cells. As shown in the right panel of Fig. 6B, theFig. 5. “Senescence” marker expression on CD4+ and CD8+ cells. PBMC were stained with CD
CD57+ (bottom left) cells in 11 young controls (black squares), 21 healthy old (black circles
right) and of CD8+KLRG1+ (bottom right) cells of young (black squares), healthy old (bla
tween control subjects and AD have been evaluated by Mann–Whitney nonparametric U tepercentage of CD4+CD25+FoxP3+CD127low T cells is higher in
both elderly controls as well as AD patients compared to the young,
but there is no difference between old controls and AD. This suggests
that AD patients have increased levels of CD4+ T cell activation but not
Tregs. No signiﬁcant differences were observed comparing CD24+
CD25+ obtained from subjects with mild vs moderate AD (data not
shown).4. Discussion
Alzheimer's disease is the most common form of dementia and
represents one of the main causes of disabilities among elderly peo-
ple. The diagnosis of AD is made following clinical criteria and only
post-mortem autopsy can really conﬁrm the disease (McKhann
et al., 1984). Such clinical criteria do not allow early diagnosis of Alz-
heimer's disease even if the pathological alterations are present years
before a certain diagnosis. The availability of reliable minimally-
invasive biomarkers for AD progression and especially for incipient
AD would be vital for an early diagnosis and a timely start of appro-
priate treatment to slow disease progression (Schupf et al., 2008;
Mocali et al., 2004; Uberti et al., 2010; Padovani et al., 2001).
The accumulation of senile plaques in the CNS formed by Aβ de-
posits is the main hallmark of the disease. For this reason AD has been
always considered as a brain disease (Selkoe, 2001). Recently it was
suggested that the inﬂammation induced by the accumulation of Aβ is
not an only a local phenomenon but can induce systemic symptoms
or be caused by systemic events (Britschgi and Wyss-Coray, 2007;
Richartz-Salzburger et al., 2007; Fiala et al., 2005). Moreover, it is likely
that Aβ is not only accumulated in the brains of AD patients, but is also
present in the periphery and can be detected in the blood (Britschgi and
Wyss-Coray, 2007; Mayeux et al., 2003; Sagare et al., 2011).
In this study we have tested the hypothesis that patients suf-
fering from Alzheimer's disease show systemic changes at the immu-
nological level, consistent with chronic antigenic stress potentially
resulting in immune exhaustion. This question has been sporadically3, CD4, CD8, KLRG1 and CD57. Percentages of CD4+CD57+ (upper left) and of CD8+
) and 40 AD patients (black diamonds) are shown. Frequency of CD4+KLRG1+ (upper
ck circles) and AD patients (black diamonds). Bars represent medians. Differences be-
sting with Bonferroni correction. Signiﬁcant differences are indicated by *** p≤0.0005.
Fig. 6. Percentage of activated and Treg cells within CD4+ cells of AD patients and controls. Representative dot plots of CD4+CD25+ cells in a young control (left panel), an old control
(middle panel) and an AD patient (right panel) (6A). Median of CD4+CD25+ cells in PBMC of 11 young controls (black squares), healthy old (black circles) and AD patients (black
diamonds) are shown (6B left). Percentages of CD4+CD25+Foxp3+CD127low, putative Tregs, in young (black squares), healthy old (black circles) and AD patients (black dia-
monds) (6B right). Bars represent medians. Differences between control subjects and AD have been evaluated by Mann–Whitney nonparametric U testing with Bonferroni correc-
tion. Signiﬁcant differences are indicated by *** p≤0.0005.
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may have been partly the result of technical issues with analytic tech-
niques, among other possibilities, especially regarding AD diagnostic
criteria. A signiﬁcant decrease of B and T cell percentages with-
out changes of natural killer (NK) cells was previously reported
(Richartz-Salzburger et al., 2007). These and other investigators also
reported a slight increase in the percentage of CD4+ T cells and a de-
crease of CD8+ cells (Richartz-Salzburger et al., 2007; Lombardi et al.,
1999). These data are not in complete agreement with other reports
of no differences in the percentage and absolute number of CD3+ T
cells, NK cells or CD4+ and CD8+ T cells (Speciale et al., 2007). In
our own pilot study we showed that major changes are seen within
the CD4+T cell subset inmild AD patients compared to healthy elder-
ly controls (Larbi et al., 2009) whereas the more marked changes in
the CD8 subsets were seen equally in both patients and age-matched
controls. To conﬁrm and extend our previous ﬁndings in a different
population (Italian not Canadian), here we tested a larger group of
AD patients (n=40, one group of mild and one group of moderate
AD) compared to healthy old (n=21) and young subjects (n=11)
using multiparameter ﬂow cytometry, including new markers to bet-
ter characterize the immunological proﬁle of these patients.
The analysis of costimulatorymolecules revealed a slight reduction
of CD28+CD27+ (early differentiated cells) and an increased per-
centage of CD28-CD27- (late differentiated cells) within the CD4+
subset of both mild and moderate AD patents compared to healthy el-
derly controls. We extended this analysis to include CD45 isoform ex-
pression, and found a signiﬁcantly reduced median percentage of
CD28+CD27+CD45RA+CD45RO- naïve CD4+ T cells in AD pa-
tients compared to old controls and a reciprocal increase of CD4+
CD28-CD27-CD45RA+CD45RO+late-differentiated memory cells.
Furthermore, we tested the expression of the potential senescence
markers CD57 and KLRG1 on these cell subpopulations. The resultswith KLRG-1 revealed the most marked differences found here be-
tween AD and age-matched controls, with highly signiﬁcantly greater
percentages of CD4+ T cells carrying this marker in the former. The
CD57 marker was not informative in this respect. Neither were any
of thesemarkers informative within the CD8 subset, probably because
the age-associated changes already seen in the controls were so
marked that any additional alterations in the patient group were not
visible. We know that the age-associated changes seen in CD8+ T
cells are predominantly caused by persistent infection with, and
hence chronic antigenic stimulation by, CMV, because CMV-negative
individuals do not manifest these changes at older age (Chidrawar
et al., 2009; Derhovanessian et al., 2010). In contrast, the CD4+ cells
are only marginally or much less affected by CMV serostatus
(Derhovanessian et al., 2010). Thus, the striking ﬁndings of differences
within the CD4 subset between AD patients and age-matched controls
reported here cannot be caused by CMV; also all elderly controls as
well as AD patients were CMV-seropositive. Because all young con-
trols were CMV-seronegative, the even more marked differences
between young and old groups are likely to be predominantly a result
of CMV stratiﬁcation. It was discussed by Goronzy et al. that there is an
effective homeostatic controlmechanism that allows themaintenance
of an appropriate number of naïve CD4+ T cells in elderly people, in
contrast with the CD8+ compartment that is more shifting with a
decrease of naïve CD8+ cells already during middle age (Goronzy
et al., 2007). Only in some pathological conditions with inﬂammatory
components (e.g. rheumatoid arthritis) it was shown that chronic
antigenic stress can be responsible for premature immunosenescence
of CD4+ cells (Weyand and Goronzy, 2002). We hypothesize that the
differences in CD4+naïve, memory and late differentiated (KLRG1+)
T cell distribution between AD and age-matched controls are causes
by chronic antigenic stimulation by Aβ present in the blood but this
has not been directly tested and a differential effect of CMV in AD-
58 M. Pellicanò et al. / Journal of Neuroimmunology 242 (2012) 52–59vs-age matched controls cannot be ruled out. Alternatively the shift
from naïve to latememory CD4+ cells in AD patients can be the result
of the capture of Aβ by local APC in the brain and the migration of
these cells towards secondary lymph nodes inducing T cell stimula-
tion, as suggested by Monsonego et al. (Monsonego et al., 2003). The
present results are consistent with our previous report of a pilot
study of mild AD patients (Larbi et al., 2009), but extend that study be-
yond the diagnosis of mild AD to include moderate AD. Moreover, the
employment of a different set of markers to deﬁne naïve and differen-
tiatedmemory cells in these two studies in patients from two different
countries, nonetheless with consistent results, suggests that these
ﬁndings are likely to be robust. Furthermore, it may be of consequence
that the immune proﬁle seen here in moderate AD is already present
in the mild AD group. This suggests that immune changes occur
early in disease progression and raises the possibility that they may
occur even before cognitive symptoms manifest. If this were so, it
has implications for early diagnosis of alterations leading to the future
development of AD. We are currently testing this possibility in pa-
tients with mild cognitive or no impairment.
In our previous paper we also showed a higher percentage of CD4+
CD25+ putative Treg cells in AD compared to healthy controls (Larbi
et al., 2009). However, the IL 2rα chain (CD25) expressed on Tregs is
also expressed on activated cells. To better identify these cells we
used several other Tregmarkers, and found amarkedly higher frequen-
cy only of CD4+CD25+FoxP3- cells (i.e. activated T cells, not Tregs) in
AD patients compared to old controls. These data are in agreementwith
others reporting a higher frequency of activated cells in the PBMC of AD
patients (Pellicanò et al., 2010; Monsonego et al., 2003; Miscia et al.,
2009; Ciccocioppo et al., 2008), but seem discordant with a recent re-
port on increased levels of Tregs in AD (Saresella et al., 2010). The pres-
ence of activatedCD4+T cellsmight be the result of Aβ-speciﬁc chronic
T cell stimulation, creating a pro-inﬂammatory environment, and en-
hancing disease progression. Possibly, the level of Treg induction de-
pends on disease progression, because Sarasella et al. found greater
suppressive activity in mild cognitively impaired patients than in AD
patients (Saresella et al., 2010).
We conclude that there is a common peripheral immune proﬁle for
Alzheimer's disease which mainly involves CD4+ T cells, changes to
which are consistent with chronic antigenic stress leading to immune
exhaustion.Whether Aβ is really the driving force is unknownbut efforts
will be concentrated on this issue in order to deﬁne how andwhy CD4+
T cells undergo changes in AD. It will be crucial to determine whether
such changes to CD4 T cells precede the development of AD, whether
they are discernible in MCI, or even in people not yet showing any cog-
nitive impairment. To this end,we are going to study the immune proﬁle
of different forms of dementia to see whether the differences we ob-
served for CD4+ cells are speciﬁc to AD and can be used as biomarkers
for early diagnosis. Moreover, focusing intervention efforts on CD4 cells
to alleviate their potential dysregulation could be of therapeutic beneﬁt.
This could possibly be approached by targeting CCR5.
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